Vemurafenib Doubles Survival Of Metastatic Melanoma Patients
A report published this week in the New England Journal of Medicine shows that the 50 percent of metastatic melanoma patients with a specific genetic mutation benefit from the drug Vemurafenib — increasing median survival from about 6 months to 15.9 months. In patients who responded, the drug stopped cancer progression for a median 6.7 months.
“For melanoma patients with a BRAF V600 mutation, this drug is a breakthrough. Not a cure, but a major breakthrough,” says Karl Lewis, MD, investigator at the University of Colorado Cancer Center, associate professor at the University of Colorado School of Medicine, and one of the study´s authors.
Lewis notes that until about 18 months ago, no drug existed for metastatic melanoma – the most dangerous form of skin cancer – that was proven to extend survival past that of patients who chose not to treat the disease. The CU Cancer Center is a leading treatment center for metastatic melanoma, and has been instrumental in enrolling patients in trials of this new category of melanoma drugs – BRAF inhibitors.
The BRAF mutation is a known oncogene — a gene that when mutated causes cancer. Specifically, the BRAF V600 mutation signals a cell to grow without bounds. Vemurafenib is a BRAF inhibitor. The mutation turns cancer on and Vemurafenib turns it off.
And turning off BRAF in the approximately 100,000 patients diagnosed worldwide each year with BRAF-positive metastatic melanoma more than doubles their time of survival.
“Rarely do we see results this dramatic,” says Lewis. “This represents a new standard of care for patients with metastatic melanoma harboring a BRAF mutation.”
Funded by Hoffmann—La Roche; ClinicalTrials.gov number, NCT00949702.
On the Net: